Upregulation of the FLT3 ligand following chemotherapy is another mechanism that contributes to both chemotherapy and FLT3 inhibitor resistance in AML, especially in tumor cells that co-express FLT3-ITD and FLT3 wild-type alleles [32, 33]. The gene discussed is FLT3; the disease is acute myeloid leukemia.